Audentes Therapeutics (NASDAQ:BOLD)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued to investors on Friday, March 9th. They currently have a $56.00 price target on the biotechnology company’s stock. Wedbush’s price target indicates a potential upside of 95.60% from the company’s current price. Wedbush also issued estimates for Audentes Therapeutics’ FY2022 earnings at $12.00 EPS.
BOLD has been the subject of several other research reports. Zacks Investment Research downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. BidaskClub downgraded Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. HC Wainwright set a $37.00 price objective on Audentes Therapeutics and gave the stock a “buy” rating in a report on Friday, March 9th. William Blair reiterated a “buy” rating on shares of Audentes Therapeutics in a report on Friday, January 5th. Finally, BMO Capital Markets assumed coverage on Audentes Therapeutics in a research note on Tuesday, December 5th. They issued an “outperform” rating and a $35.00 target price on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the company. Audentes Therapeutics presently has a consensus rating of “Buy” and an average target price of $35.56.
Audentes Therapeutics stock traded down $1.42 during midday trading on Friday, reaching $28.63. The stock had a trading volume of 387,652 shares, compared to its average volume of 443,573. Audentes Therapeutics has a 12 month low of $13.90 and a 12 month high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings data on Thursday, March 8th. The biotechnology company reported ($0.82) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.91) by $0.09. sell-side analysts forecast that Audentes Therapeutics will post -3.43 EPS for the current year.
In related news, VP Suyash Prasad sold 1,900 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, March 26th. The stock was sold at an average price of $30.00, for a total transaction of $57,000.00. Following the sale, the vice president now owns 1,900 shares of the company’s stock, valued at approximately $57,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Orbimed Advisors Llc sold 433,210 shares of Audentes Therapeutics stock in a transaction that occurred on Tuesday, March 6th. The shares were sold at an average price of $35.11, for a total value of $15,210,003.10. The disclosure for this sale can be found here. Insiders sold 1,127,407 shares of company stock worth $39,177,415 in the last ninety days. Corporate insiders own 47.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its holdings in shares of Audentes Therapeutics by 13.2% in the 4th quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock worth $42,452,000 after purchasing an additional 158,576 shares during the period. Jennison Associates LLC boosted its holdings in shares of Audentes Therapeutics by 1.2% in the 4th quarter. Jennison Associates LLC now owns 853,822 shares of the biotechnology company’s stock worth $26,682,000 after purchasing an additional 9,762 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Audentes Therapeutics by 10.4% in the 3rd quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock worth $21,885,000 after purchasing an additional 73,809 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after purchasing an additional 383,837 shares during the period. Finally, Citadel Advisors LLC boosted its holdings in shares of Audentes Therapeutics by 206.2% in the 4th quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock worth $10,612,000 after purchasing an additional 228,667 shares during the period. Institutional investors and hedge funds own 66.96% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Audentes Therapeutics’ (BOLD) “Outperform” Rating Reaffirmed at Wedbush” was originally published by Enterprise Leader and is the property of of Enterprise Leader. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://theenterpriseleader.com/2018/04/02/audentes-therapeutics-bold-rating-reiterated-by-wedbush.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.